Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6418-6431

  Modlich, Olga ^a   Prisack, Hans Bernd ^a   Munnes, Marc ^b   Audretsch, Werner ^c   Bojar, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c City Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL; PROTEIN P21;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; UPREGULATION;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLUSTER ANALYSIS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 5144229762     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1031     Document Type: Article

References (83)

1. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 2003;88:406-12.
2. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
3. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women Clinical correlation on 547 patients. Cancer (Phila) 1986;57:1171-80.
4. Hupperets PS, Volovics L, Schouten LJ, et al. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol 1997;20:546-51.
5. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
6. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.
7. Kun Y, How LC, Hoon TP, et al. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 2003;12:3245-58; Epub 2003 Oct 21.
8. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer (Phila) 2003;97:1758-65.
9. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-7.
10. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature (Lond) 2000;406:747-52.
11. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 2003;100:8418-23; Epub 2003 Jun 26.
12. Dressman MA, Walz TM, Lavedan C, et al. Genes that cocluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J 2001;1:135-41.
13. Dressman MA, Baras A, Malinowski R, et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003;63:2194-9.
14. Tagliabue E, Agresti R, Carcangiu ML, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003;362:527-33.
15. Zhu G, Reynolds L, Crnogorac-Jurcevic T, et al. Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene 2003;22:3742-8.
16. Mackay A, Jones C, Dexter T, et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003;22:2680-8.
17. Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum D. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 2003;103:565-71.
18. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003;9:2406-15.
19. Ahr A, Holtrich U, Solbach C, et al. Molecular classification of breast cancer patients by gene expression profiling. J Pathol 2001;195:312-20.
20. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
21. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 2002;161:1171-85.
22. Martin KJ, Kritzman BM, Price LM, et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res 2000;60: 2232-8.
23. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
24. Ahr A, Karn T, Solbach C, et al. Identification of high risk breastcancer patients by gene expression profiling. Lancet 2002;359:131-2.
25. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
26. Bertucci F, Houlgatte R, Benziane A, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000;9:2981-91.
27. Bertucci F, Nasser V, Granjeaud S, et al. Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002;11:863-72.
28. Bertucci F, Houlgatte R, Granjeaud S, et al. Prognosis of breast cancer and gene expression profiling using DNA arrays. Ann N Acad Sci 975:217-31, 2002.
29. Gruvberger SK, Ringner M, Eden P, et al. Expression profiling to predict outcome in breast cancer: the influence of sample selection. Breast Cancer Res. 2003;5:23-6; Epub 2002 Oct 11.
30. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415: 530-6.
31. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, Van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003;100:15901-5.
32. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
33. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001;98:11462-7; Epub 2001 Sep 18.
34. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
35. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 2003;100:10393-8; Epub 2003 Aug 13.
36. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100: 5974-9; Epub 2003 Apr 24.
37. Jenssen TK, Kuo WP, Stokke T, Hovig E. Associations between gene expressions in breast cancer and patient survival. Hum Genet 2002;111:411-20; Epub 2002 Aug 23.
38. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:5679-84.
39. Lonning PE, Sorlie T, Perou CM, Brown PO, Botstein D, Borresen-Dale AL. Microarrays in primary breast cancer - lessons from chemotherapy studies. Endocr Relat Cancer 2001;8:259-63.
40. Buchholz TA, Stivers DN, Stec J, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002;8:461-8.
41. Sotiriou C, Powles TJ, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer Breast Cancer Res 2002;4:R3.
42. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
43. Korn EL, McShane LM, Troendle JF, Rosenwald A, Simon R. Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002;86:1093-6.
44. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
45. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-94.
46. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003;98:1150-60.
47. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-52.
48. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
49. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
50. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
51. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-84.
52. Wolff AC, Davidson NE. Early operable breast cancer. Curr Treat Options Oncol 2000;1:210-20.
53. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist 2002;7:239-45.
54. Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997;76:1099-105.
55. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
56. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.
57. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (Phila) 2000;89:2145-52.
58. Gluck S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002;9(Suppl):16-27.
59. Trudeau M, Pagani O. Epirubicin in combination with the taxanes. Semin Oncol 2001;28(Suppl 12):41-50.
60. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet 2001;2:418-27.
61. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
62. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000;285:194-204.
63. Jelinsky SA, Harris HA, Brown EL, et al. Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney. Endocrinology 2003;144:701-10.
64. Eriksson L, Johansson E, Lindgren F, Sjostrom M, Wold S. Megavariate analysis of hierarchical QSAR data. J Comput Aided Mol Des 2002;16:711-26.
65. Perez-Enciso M, Tenenhaus M. Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum Genet 2003;112:581-92; Epub 2003 Feb 27.
66. Nguyen DV, Rocke DM. Multi-class cancer classification via partial least squares with gene expression profiles. Bioinformatics 2002; 18:1216-26.
67. Eriksson L, Johansson E, Kettaneh-Wold N, and Wold S. Multi-and megavariate data analysis. Principles and applications. Umetrics Academy: Umea, Sweden; 2001:533.
68. Tenenhaus M. La régression PLS. Paris: Editions Technip; 1998.
69. Parton M, Krajewski S, Smith I, et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 2002;8:2100-8.
70. Meyn RE, Stephens LC, Hunter NR, Milas L. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994;33:410-14.
71. Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995;6: 443-50.
72. Ellis PA, Smith IE, Detre S, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998;48:107-16.
73. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (Phila) 2000;89:2145-52.
74. Modlich O, Prisack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004;10:3410-21.
75. Rogojina AT, Orr WE, Song BK, Geisert EE Jr. Comparing the use of Affymetrix to spotted oligonucleotide microarrays using two retinal pigment epithelium cell lines. Mol Vis 2003;9:482-96.
76. Jarvinen AK, Hautaniemi S, Edgren H, et al. Are data from different gene expression microarray platforms comparable? Genomics 2004;83: 1164-8.
77. Fan Y, Borowsky AD, Weiss RH. An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2003;2:773-82.
78. Gorospe M, Wang X, Holbrook NJ. Functional role of p21 during the cellular response to stress. Gene Expr 7:377-85, 1999.
79. Liu T, Bauskin AR, Zaunders J, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-40.
80. Baek SJ, Wilson LC, Lee CH, Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301:1126-31.
81. Tirone F. The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 2001;187:155-65.
82. Duriez C, Falette N, Audoynaud C, et al. The human BTG2/TIS21/ PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene (Amst) 282:207-14, 2002.
83. Rouault JP, Falette N, Guehenneux F, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996;14:482-6.